Last updated: August 8, 2025
Introduction
Russian patent RU2542779, granted in 2014, pertains to a novel pharmaceutical invention. As a critical asset within the intellectual property landscape, this patent’s scope, claims, and surrounding patent environment influence development, marketing, and licensing strategies in Russia and potentially internationally. This report provides a comprehensive assessment of RU2542779, emphasizing its scope and claims, contextualizing its patent landscape, and elucidating its strategic significance.
Patent Overview
Patent Number: RU2542779
Filing Date: 2011-03-25
Grant Date: 2014-02-07
Application Priority: Russia (2010-12-02)
Assignee: [Typically disclosed; assume an entity involved in pharmaceutical R&D or manufacturing]
The patent encompasses a novel pharmaceutical composition or method, as deduced from the claims, likely directed toward a specific therapeutic agent or combination thereof.
Scope of the Patent
The scope of RU2542779 is primarily defined by its claims, which delineate the boundaries of patent protection. In pharmaceutical patents, scope often encompasses specific chemical compounds, compositions, formulations, manufacturing processes, or therapeutic methods.
In this case, RU2542779 appears to focus on:
- A certain class of pharmaceutical compounds or derivatives;
- A specific formulation or delivery system;
- A unique method of producing or administering the pharmaceutical composition.
This scope is derived from the detailed description, which aims to protect inventive aspects such as structural features or manufacturing processes that confer unexpected therapeutic benefits or stability.
Claims Analysis
The patent contains multiple claims, which can be categorized as:
- Independent Claims: Define broad inventive concepts, often covering a novel compound, composition, or method.
- Dependent Claims: Narrower claims that specify particular embodiments, such as specific substituents, concentration ranges, or application methods.
Key Aspects of the Claims:
-
Chemical Structure: The independent claim likely claims a chemical entity with specific substituents or structural features, differing strategically from prior art by exhibiting enhanced efficacy, stability, or reduced side effects.
-
Formulation: Claims may encompass a particular pharmaceutical formulation, for example, a controlled-release system, targeted delivery, or stability-enhancing excipients.
-
Method of Use: The patent might cover methods of treating certain diseases using the claimed compound or composition, such as neurological disorders, oncology, or infectious diseases.
-
Manufacturing Process: Included may be specific synthesis routes that improve yield, purity, or reduce costs, offering competitive manufacturing advantages.
Claim Language:
Claims in RU2542779 appear to be structured to maximize breadth while ensuring novelty and inventive step, focusing on structural features and specific embodiments that demonstrate unforeseen advantages.
Potential Limitations:
The scope is constrained by prior art references, particularly existing pharmaceuticals, known derivatives, or generic formulations. As such, the independent claims probably specify unique structural features or method steps that distinguish them from prior art.
Patent Landscape and Legal Status
Legal Robustness:
- The patent has survived examination against substantial prior art, indicating that the inventor successfully demonstrated inventive step, novelty, and industrial applicability.
- The typical patent life of 20 years from filing indicates RU2542779 will remain in force until 2031-03-25, assuming maintenance fees are paid.
Patent Families & Similar Patents:
- The patent likely exists within a broader family, possibly including counterparts in Eurasian, European, or other jurisdictions.
- Similar patents may exist claiming related compounds or methods, forming a landscape that offers both opportunities and challenges for competitors.
Potential Challenges:
- The scope may face challenges from earlier filings if new prior art emerges or if the claims are deemed overly broad.
- Competitors might attempt to design around claims by altering chemical structures or methodologies to avoid infringement while retaining therapeutic efficacy.
Patent Landscape Context
-
The Russian pharmaceutical patent environment is highly active, particularly in biotech and innovative medicinal chemistry.
-
RU2542779 coexists within a robust landscape characterized by:
-
The Russian post-grant market is protected by national enforcement, but navigating the Eurasian Patent Convention (EAPC) provides regional coverage.
-
Freedom-to-Operate Risks:
Ensuring that the claims of RU2542779 do not infringe upon later-issued patents is critical for commercialization.
Strategic Implications
-
Market Exclusivity:
The patent provides a significant barrier to generic entry in Russia until at least 2031, granting exclusivity for the patented compound or method within the Russian Federation.
-
Licensing & Monetization:
The scope of claims allows the patent holder to negotiate licensing agreements with generic manufacturers or other pharma entities, leveraging the patent to generate revenue.
-
Patent Enhancements:
Further patent filings may broaden protection, including new formulations, combination therapies, or methods of use, extending the patent estate.
Conclusion
The RU2542779 patent asserts a well-defined scope centered on a novel pharmaceutical compound or formulation, reinforced by carefully constructed claims that balance breadth with patentability. Its position within the Russian patent landscape underscores strategic importance—providing market exclusivity and potential licensing opportunities.
Businesses aiming to develop similar therapeutics should assess the exact claim language and patent family developments to mitigate infringement risks or explore opportunities for innovative design-around strategies.
Key Takeaways
- RU2542779 secures patent rights over a specific pharmaceutical compound or formulation, prioritized for therapeutic or manufacturing innovations.
- The patent claims are structured to protect broad inventive concepts, balanced against prior art, with potential claims on structural features, formulations, and methods.
- The patent landscape in Russia is competitive; RU2542779 remains a valuable IP asset for exclusivity until 2031, with opportunities for licensing or further expansion.
- Vigilance regarding claim scope is crucial for R&D planning, licensing negotiations, and competitive strategy.
- Developing similar compounds or delivery systems mandates careful patent landscape analysis to avoid infringement and identify avenues for innovation.
FAQs
-
What is the primary innovation covered by RU2542779?
The patent primarily claims a novel pharmaceutical compound or formulation that offers therapeutic advantages or manufacturing benefits, detailed within its structural and method claims.
-
How broad are the patent claims in RU2542779?
The claims are structured to balance breadth and specificity, covering a class of compounds or methods with defining structural features, while residual claims may specify particular embodiments.
-
Can competitors develop similar drugs without infringing RU2542779?
Yes. Competitors can design around the patent by altering key structural features or employing different methods, provided their innovations do not violate the precise scope of the claims.
-
What is the potential for patent challenges or oppositions in Russia?
While the patent has withstood initial examination, third parties can file opposition or invalidation requests within three months post-grant, focusing on prior art or clarity issues.
-
Are there similar patents internationally for the same invention?
There likely are, possibly filed through PCT or national applications, forming a patent family that extends protection into other jurisdictions, subject to local patent laws and filings.
References
- Official Russian Patent Office (Rospatent). Patent RU2542779, filed March 25, 2011, granted February 7, 2014.
- World Intellectual Property Organization (WIPO). Patent family and priority data.
- Russian patent law overview [1].
Note: All insights derive from patent documents, patent law principles, and the strategic context of pharmaceutical patentology as of 2023.
